Moderna, Inc. (MRNA) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $55.73 (+6.77%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 3, 2026 | Andrew Tsai | Jefferies | $37.00 | -33.6% |
| Feb 17, 2026 | Luca Issi | RBC Capital | $30.00 | -46.2% |
| Feb 17, 2026 | Cory Kasimov | Evercore ISI | $35.00 | -37.2% |
| Nov 21, 2025 | Luca Issi | RBC Capital | $25.00 | -55.1% |
| Aug 1, 2025 | Geoff Meacham | Citigroup | $40.00 | -28.2% |
| Aug 1, 2025 | Jessica Fye | J.P. Morgan | $26.00 | -53.4% |
| Aug 1, 2025 | Cory Kasimov | Evercore ISI | $32.00 | -42.6% |
| Aug 1, 2025 | Matthew Harrison | Morgan Stanley | $32.00 | -42.6% |
| Feb 14, 2025 | Cory Kaimov | Evercore ISI | $50.00 | -10.3% |
| Feb 14, 2025 | Jessica Fye | J.P. Morgan | $45.00 | -19.3% |
| Nov 18, 2024 | Edward Tenthoff | Piper Sandler | $69.00 | +23.8% |
| Nov 18, 2024 | Yifeng Liu | HSBC | $58.00 | +4.1% |
| Oct 17, 2024 | Courtney Breen | Bernstein | $55.00 | -1.3% |
| Oct 14, 2024 | Michael Yee | Jefferies | $55.00 | -1.3% |
| Sep 13, 2024 | Edward Tenthoff | Piper Sandler | $115.00 | +106.3% |
| Sep 13, 2024 | Luca Issi | RBC Capital | $75.00 | +34.6% |
| Sep 13, 2024 | Leah Rush Cann | Loop Capital Markets | $238.00 | +327.0% |
| Sep 12, 2024 | Michael Yee | Jefferies | $65.00 | +16.6% |
| Sep 12, 2024 | Cory Kasimov | Evercore ISI | $105.00 | +88.4% |
| Sep 12, 2024 | Matthew Harrison | Morgan Stanley | $94.00 | +68.7% |
Top Analysts Covering MRNA
MRNA vs Sector & Market
| Metric | MRNA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.24 | 2.40 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | -19.7% | +11475.1% | +17.1% |
| P/E Ratio | -6.55 | 3.92 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $74M | $132M | $196M | 10 |
| 2026-09-30 | $538M | $974M | $1.38B | 5 |
| 2026-12-31 | $403M | $730M | $1.03B | 5 |
| 2027-03-31 | $93M | $169M | $239M | 5 |
| 2027-06-30 | $76M | $137M | $195M | 5 |
| 2027-09-30 | $698M | $1.26B | $1.79B | 5 |
| 2027-12-31 | $627M | $1.14B | $1.61B | 5 |
| 2028-12-31 | $3.12B | $3.14B | $3.17B | 16 |
| 2029-12-31 | $4.17B | $5.08B | $7.55B | 15 |
| 2030-12-31 | $5.56B | $6.79B | $10.08B | 15 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-2.37 | $-2.10 | $-1.59 | 10 |
| 2026-09-30 | $-1.30 | $-0.84 | $-0.35 | 4 |
| 2026-12-31 | $-2.15 | $-1.39 | $-0.58 | 4 |
| 2027-03-31 | $-3.18 | $-2.06 | $-0.86 | 4 |
| 2027-06-30 | $-3.35 | $-2.17 | $-0.91 | 4 |
| 2027-09-30 | $-0.33 | $-0.21 | $-0.09 | 4 |
| 2027-12-31 | $-0.93 | $-0.60 | $-0.25 | 4 |
| 2028-12-31 | $-6.17 | $-2.89 | $0.69 | 14 |
| 2029-12-31 | $-0.14 | $-0.08 | $-0.06 | 8 |
| 2030-12-31 | $1.99 | $2.60 | $4.25 | 12 |
Frequently Asked Questions
What is the analyst consensus for MRNA?
The consensus among 8 analysts covering Moderna, Inc. (MRNA) is Hold with an average price target of $35.67.
What is the highest price target for MRNA?
The highest price target for MRNA is $350.00, set by Jasper Hellweg at Argus Research on 2022-01-06.
What is the lowest price target for MRNA?
The lowest price target for MRNA is $25.00, set by Luca Issi at RBC Capital on 2025-11-21.
How many analysts cover MRNA?
8 analysts have issued ratings for Moderna, Inc. in the past 12 months.
Is MRNA a buy or sell right now?
Based on 8 analyst ratings, MRNA has a consensus rating of Hold (3.00/5) with a -19.7% upside to the consensus target of $35.67.
What are the earnings estimates for MRNA?
Analysts estimate MRNA will report EPS of $-2.10 for the period ending 2026-06-30, with revenue estimated at $132M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.